Last reviewed · How we verify
HDM1005 4
At a glance
| Generic name | HDM1005 4 |
|---|---|
| Sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase Ib Clinical Study of HDM1005 Injection (PHASE1)
- Phase Ia Clinical Study of HDM1005 Injection (PHASE1)
- Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes (PHASE3)
- Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus (PHASE2)
- A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HDM1005 4 CI brief — competitive landscape report
- HDM1005 4 updates RSS · CI watch RSS
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. portfolio CI